Mirum Pharmaceuticals, Inc. MIRM Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -139.8%-120pp | -4.2%+21.8pp | -8.9%+22.4pp | -13.3%+27.7pp | -20.1%+28.3pp | |
| Net margin | -140.2%-120pp | -4.5%+21.6pp | -8.8%+23.7pp | -13.6%+27.6pp | -20.4%+50.4pp | |
| Returns | ||||||
| Return on equity | -335.8%-303pp | -8.6%+28.4pp | -15.8%+24.0pp | -24.2%+46.8pp | -33.1%+51.3pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×+0.2× | 0.7×+0.2× | 0.6×+0.2× | 0.6×+0.1× | 0.6×+0.1× | |
| Liquidity | ||||||
| Current ratio | 2.1×-1.1× | 2.7×-0.4× | 3.3×0.0× | 3.1×-0.1× | 3.2×-0.5× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $4.12-13.6% | $6.27+32.0% | $5.12+5.5% | $5.13+5.8% | $4.77-4.6% | |
| Valuation | ||||||
| Market capitalization | $5.57B+152% | $4.08B+106% | $3.68B+99.9% | $2.53B+57.8% | $2.21B+88.1% | |
| Price / sales | 9.8×+4.0× | 7.8×+1.9× | 7.8×+1.8× | 5.9×-0.2× | 5.8×+0.6× | |
| Price / book | 23×+13.5× | 13×+4.2× | 12.6×+4.7× | 9.9×+2.9× | 9.5×+4.5× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Mirum Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Mirum Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
